John M. Burke, MD, discusses research with tafasitamab (MOR208) in lymphoma.
John M. Burke, MD, associate chair of the Hematology Research Program for US Oncology and medical oncologist and hematologist at Rocky Mountain Cancer Centers, discusses research with tafasitamab (MOR208) in lymphoma.
Tafasitamab has been evaluated in a phase 1 trial in patients with relapsed lymphoma, says Burke. There is also evidence that the anti-CD19 antibody has activity in follicular lymphoma and large cell lymphoma. Moreover, tafasitamab has been evaluated in combination with lenalidomide (Revlimid) in patients with relapsed lymphoma.
The agent is currently under investigation in the phase 1b First-MIND trial in combination with rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone with or without lenalidomide in patients with newly diagnosed diffuse large B-cell lymphoma. Investigators plan to keep the First-MIND trial, which is an international study being conducted at different sites around the world, open and enrolling for about 6 to 12 months, concludes Burke.